[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL160097A0 - Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof - Google Patents

Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Info

Publication number
IL160097A0
IL160097A0 IL16009702A IL16009702A IL160097A0 IL 160097 A0 IL160097 A0 IL 160097A0 IL 16009702 A IL16009702 A IL 16009702A IL 16009702 A IL16009702 A IL 16009702A IL 160097 A0 IL160097 A0 IL 160097A0
Authority
IL
Israel
Prior art keywords
ylidene
carboxamide
diethylamino
indole
pyrrole
Prior art date
Application number
IL16009702A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL160097(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL160097A0 publication Critical patent/IL160097A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
IL16009702A 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof IL160097A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (fr) 2001-08-15 2002-08-13 Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes

Publications (1)

Publication Number Publication Date
IL160097A0 true IL160097A0 (en) 2004-06-20

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16009702A IL160097A0 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Country Status (43)

Country Link
US (2) US20030069298A1 (fr)
EP (3) EP3168218B1 (fr)
JP (1) JP4159988B2 (fr)
KR (1) KR100639281B1 (fr)
CN (2) CN100364991C (fr)
AP (1) AP1660A (fr)
AR (1) AR036261A1 (fr)
AU (1) AU2002324684B2 (fr)
BG (1) BG108553A (fr)
BR (1) BR0211612A (fr)
CA (1) CA2455050C (fr)
CO (1) CO5550431A2 (fr)
CU (1) CU23713B7 (fr)
CY (1) CY1121552T1 (fr)
CZ (1) CZ2004196A3 (fr)
DK (2) DK1419151T3 (fr)
EA (1) EA006445B9 (fr)
EC (1) ECSP044975A (fr)
ES (3) ES2623094T3 (fr)
GE (1) GEP20063777B (fr)
HK (2) HK1066542A1 (fr)
HR (1) HRP20040112B1 (fr)
HU (1) HU229206B1 (fr)
IL (1) IL160097A0 (fr)
IS (1) IS7147A (fr)
MA (1) MA27058A1 (fr)
ME (1) ME00414B (fr)
MX (1) MXPA04001452A (fr)
MY (1) MY139383A (fr)
NO (1) NO326508B1 (fr)
NZ (1) NZ531232A (fr)
OA (1) OA12650A (fr)
PL (1) PL216524B1 (fr)
PT (2) PT3168218T (fr)
RS (1) RS53251B (fr)
SI (2) SI1419151T1 (fr)
SK (1) SK902004A3 (fr)
TN (1) TNSN04028A1 (fr)
TR (1) TR201900509T4 (fr)
TW (1) TWI269796B (fr)
UA (1) UA76483C2 (fr)
WO (1) WO2003016305A1 (fr)
ZA (1) ZA200400706B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2004196A3 (cs) 2001-08-15 2005-01-12 Pharmacia & Upjohn Company Krystaly obsahující sůl N-[2-(diethylamino)ethyl]-5-[(5-fluor-2-oxo-3H-indol-3-yliden) methyl]-2,4-dimethyl-1H-pyrrol 3-karboxamidu s kyselinou jablečnou, způsob jejich výroby a kompozice na jejich bázi
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
JP4933259B2 (ja) * 2003-10-02 2012-05-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロール置換インドリノン化合物の塩および多形
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
DE602005023474D1 (en) * 2004-07-22 2010-10-21 Lilly Co Eli Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridincarbonsäureamid-hemisuccinatsalz
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
AU2006293644B2 (en) 2005-09-19 2012-05-31 Zoetis Services Llc Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (fr) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
CA2709083A1 (fr) * 2007-12-12 2009-06-18 Medichem S.A. Formes polymorphes d'une 2-indolinone substituee par 3-pyrrole
EP2113248A1 (fr) 2008-04-29 2009-11-04 Ratiopharm GmbH Composition pharmaceutique comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (fr) 2008-02-13 2009-08-19 Ratiopharm GmbH Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US20110112164A1 (en) * 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (fr) * 2008-03-06 2009-09-09 Ratiopharm GmbH Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide
PL2274303T3 (pl) * 2008-03-31 2013-03-29 Teva Pharma Sposoby otrzymywania sunitynibu i jego soli
US8466190B2 (en) 2008-04-16 2013-06-18 Natco Pharma Limited Polymorphic forms of Sunitinib base
EP2292613B1 (fr) 2008-05-23 2015-09-30 Shanghai Institute of Pharmaceutical Industry Dérivés de dihydroindolinone
SI2313371T1 (sl) * 2008-06-13 2013-02-28 Medichem, S.A. Postopek za pripravo soli 3-pirol substituirane 2-indolinonske jabolčne kisline
EP2138167A1 (fr) 2008-06-24 2009-12-30 ratiopharm GmbH Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (fr) * 2008-06-26 2009-12-30 Medichem, S.A. Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2010004339A1 (fr) 2008-07-10 2010-01-14 Generics [Uk] Limited Procédés de préparation de formes cristallines de malate de sunitinib
CA2731605A1 (fr) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib et ses sels et leurs polymorphes
EP2342195B1 (fr) * 2008-07-24 2014-09-10 Medichem, S.A. Formes cristallines d un sel de malate de 2-indolinone à substitution 3-pyrrole
US20120029046A1 (en) * 2008-08-25 2012-02-02 Generics (Uk) Limited Crystalline form of sunitinib and processes for its preparation
CN102197034A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的新型多晶型物及其制备方法
WO2010041134A1 (fr) * 2008-10-10 2010-04-15 Medichem, S.A. Procédé pour la préparation d'un sel de malate de 2-indolinone substituée par pyrrole en position 3
EP2181991A1 (fr) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Nouveaux sels de sunitinib
EP2186809A1 (fr) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. Nouvelle forme cristalline du malate de sunitinib
EP2896618A1 (fr) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphes du malate de sunitinib
NZ618004A (en) 2009-01-16 2015-06-26 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EP2255792A1 (fr) 2009-05-20 2010-12-01 Ratiopharm GmbH Composition pharmaceutique pour n-[2-(diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1h-pyrrole-3-carboxamide
WO2011004200A1 (fr) 2009-07-10 2011-01-13 Generics [Uk] Limited Nouveaux dérivés de pyrrole
AU2010296849A1 (en) 2009-09-16 2012-05-03 Ranbaxy Laboratories Limited Salts of sunitinib
US20120271056A1 (en) 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011061613A1 (fr) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Procédé de préparation de la forme cristalline ii du sel d'acide malique l du sunitinib
US20130210885A1 (en) 2010-01-29 2013-08-15 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (fr) 2010-02-09 2011-08-18 Sicor Inc. Polymorphes de sels de sunitinib
WO2011104555A2 (fr) 2010-02-25 2011-09-01 Generics [Uk] Limited Nouveau procédé
AU2011222470A1 (en) 2010-03-04 2012-09-27 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
US20160185760A1 (en) 2010-03-18 2016-06-30 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (fr) 2010-04-16 2011-10-20 Generics [Uk] Limited Procédés inédits
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2828251B1 (fr) 2012-03-23 2018-10-31 Laurus Labs Limited Procédé perfectionné pour la préparation de sunitinib et de ses sels d'addition avec un acide
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
RU2609651C2 (ru) 2012-05-04 2017-02-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
CA2838585A1 (fr) 2013-10-18 2015-04-18 Hari Babu Matta Sel de sunitinib d'acide ascorbique
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
PT3062815T (pt) 2013-11-01 2019-03-27 Pfizer Vetores para expressão de antigénios associados à próstata
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (fr) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i
WO2020216450A1 (fr) 2019-04-25 2020-10-29 Synthon B.V. Composition pharmaceutique comprenant du sunitinib amorphe
JP2022529290A (ja) * 2019-04-18 2022-06-20 メーター ヘルス インコーポレイテッド 呼吸性不整脈を処置するための方法および組成物
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179053B1 (ko) 1990-10-15 1999-03-20 알렌 제이.스피겔 인돌 유도체
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
AU4337293A (en) 1992-06-05 1994-01-04 Merck Sharp & Dohme Limited The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
ZA941586B (en) * 1993-03-12 1995-09-07 Upjohn Co Crystalline ceftiofur free acid
US6329364B1 (en) * 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) * 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) * 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
EA003754B1 (ru) * 1996-08-14 2003-08-28 Джи. Ди. Сирл Энд Ко. 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамид
KR100530601B1 (ko) * 1996-12-25 2005-11-23 니폰 가야꾸 가부시끼가이샤 시스플라틴 미분말 및 그의 제조방법
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
CN102659712A (zh) 1998-06-19 2012-09-12 帝人制药株式会社 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的多晶型体及其制备方法
AU770375B2 (en) * 1998-12-17 2004-02-19 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular CDK2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
ATE514676T1 (de) * 1999-11-24 2011-07-15 Sugen Inc Ionisierbare indolinon derivate und deren verwendung als ptk liganden
AU2001239770B2 (en) * 2000-02-15 2006-01-05 Pharmacia & Upjohn Company Pyrrole substituted 2-indolinone protein kinase inhibitors
US6316672B1 (en) * 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
CZ2004196A3 (cs) 2001-08-15 2005-01-12 Pharmacia & Upjohn Company Krystaly obsahující sůl N-[2-(diethylamino)ethyl]-5-[(5-fluor-2-oxo-3H-indol-3-yliden) methyl]-2,4-dimethyl-1H-pyrrol 3-karboxamidu s kyselinou jablečnou, způsob jejich výroby a kompozice na jejich bázi
US20110112164A1 (en) 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (fr) 2008-06-26 2009-12-30 Medichem, S.A. Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole

Also Published As

Publication number Publication date
TR201900509T4 (tr) 2019-02-21
AR036261A1 (es) 2004-08-25
HK1066542A1 (en) 2005-03-24
HRP20040112A2 (en) 2004-06-30
CO5550431A2 (es) 2005-08-31
EP1419151B1 (fr) 2014-02-26
JP2005503386A (ja) 2005-02-03
EP1419151A1 (fr) 2004-05-19
NO326508B1 (no) 2008-12-15
ZA200400706B (en) 2005-05-25
US20030069298A1 (en) 2003-04-10
MY139383A (en) 2009-09-30
EP2332934A1 (fr) 2011-06-15
ES2623094T3 (es) 2017-07-10
ES2453164T3 (es) 2014-04-04
SI1419151T1 (sl) 2014-04-30
BG108553A (bg) 2005-04-30
JP4159988B2 (ja) 2008-10-01
EP2332934B1 (fr) 2017-03-01
WO2003016305A1 (fr) 2003-02-27
US7435832B2 (en) 2008-10-14
CN1789264A (zh) 2006-06-21
RS10304A (en) 2007-02-05
UA76483C2 (en) 2006-08-15
TNSN04028A1 (fr) 2006-06-01
SK902004A3 (sk) 2005-03-04
US20070191458A1 (en) 2007-08-16
RS53251B (sr) 2014-08-29
ME00414B (me) 2011-10-10
EA200400183A1 (ru) 2004-08-26
OA12650A (en) 2006-06-19
CN100364991C (zh) 2008-01-30
GEP20063777B (en) 2006-03-27
PT1419151E (pt) 2014-03-27
KR100639281B1 (ko) 2006-10-31
EA006445B9 (ru) 2017-02-28
CU20040029A7 (es) 2008-03-14
PT3168218T (pt) 2019-01-11
ES2705063T3 (es) 2019-03-21
EA006445B1 (ru) 2005-12-29
AP2004002976A0 (en) 2004-03-31
PL368317A1 (en) 2005-03-21
HUP0700036A2 (en) 2008-10-28
CU23713B7 (es) 2011-10-05
SI3168218T1 (sl) 2019-05-31
PL216524B1 (pl) 2014-04-30
EP3168218B1 (fr) 2018-11-14
CN100439360C (zh) 2008-12-03
DK1419151T3 (da) 2014-03-31
HU229206B1 (en) 2013-09-30
CA2455050C (fr) 2007-02-20
ECSP044975A (es) 2004-03-23
NO20041054L (no) 2004-03-12
KR20040030074A (ko) 2004-04-08
TWI269796B (en) 2007-01-01
IS7147A (is) 2004-02-10
AU2002324684B2 (en) 2006-10-05
CZ2004196A3 (cs) 2005-01-12
CN1543462A (zh) 2004-11-03
BR0211612A (pt) 2004-08-24
CA2455050A1 (fr) 2003-02-27
CY1121552T1 (el) 2020-05-29
HRP20040112B1 (en) 2012-03-31
MXPA04001452A (es) 2004-05-20
NZ531232A (en) 2004-11-26
DK3168218T3 (en) 2019-01-14
MA27058A1 (fr) 2004-12-20
AP1660A (en) 2006-09-09
EP3168218A1 (fr) 2017-05-17
HK1088008A1 (en) 2006-10-27

Similar Documents

Publication Publication Date Title
IL160097A0 (en) Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
PT1488790E (pt) Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico
WO2002010154A3 (fr) Amides heterocycliques substitues
IL189358A0 (en) Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
HUP0400236A3 (en) Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride, process for their preparation and pharmaceutical compositions containing them
HK1140487A1 (en) Pharmaceutical compositions containing crystalline form (i) of lercanidipine hydrochloride (i)
IL141767A0 (en) Use of heteroaryl substituted n- (indole-2-carbonyl-) amides for treatment of infection
WO2006025070A3 (fr) Nebivolol et ses sels pharmaceutiquement acceptables, procede de preparation et compositions pharmaceutiques de nebivolol
IL162456A0 (en) A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochlor
HUP0401694A3 (en) Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use
AU2001267886A1 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
AU2003223637A1 (en) Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
IL161275A0 (en) [[2-(amino-3,4-dioxo-1cyclobuten-1-yl) amino] alkyl] acid derivatives for the treatment of pain
PL368352A1 (en) Process for preparation of $g(a)-hydroxycarboxylic acid amides
AU2003274518A8 (en) A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives
AU2003260813A8 (en) Improved process for preparation of thiazolidinedione derivatives
AU2002364804A8 (en) Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses
EP1316547A4 (fr) Nouveaux cristaux de n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)- n-(4-phenoxyphenylcarbonyl)amino]pentanamide, leur procede de production et medicaments contenant ces cristaux en tant que substance active
AU2002313179A1 (en) Processes for preparation of heterocyclic compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed